GlassScriptPhysician profile
Gerardo E Eman Greci
NPI 1588125371
$906.69
in general payments reported to CMS, 2019-2025
12 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $23.32 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $179.48 | 2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $169.97 | 2025 | Uptravi, Opsynvi, Opsumit |
| Genzyme Corporation | $122.56 | 2025 | |
| United Therapeutics Corporation | $97.78 | 2025 | Tyvaso, Remodulin, Orenitram |
| Merck Sharp & Dohme LLC | $84.63 | 2025 | Zerbaxa, Winrevair |
| Astrazeneca Pharmaceuticals LP | $83.74 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $38.94 | 2025 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.42 | 2025 | |
| Theratechnologies INC. | $30.38 | 2025 | Trogarzo, Egrifta |
| Liquidia Technologies, INC. | $22.96 | 2025 | Yutrepia |
| Takeda Pharmaceuticals U.S.A., INC. | $21.79 | 2025 | Cuvitru |
| Abbvie INC. | $17.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Eman Greci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.